Drugs / Tritanrix-HepB/Hib
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT00814710 | Mar → Nov 2009 | pneumococcal infection | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Tritanrix-HepB/Hib | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00814710 ↗ |
| Known as | TritanrixTM-HepB/Hib | “Subjects received SynflorixTM (GSK1024850A) intramuscularly in the right thigh co-administered with TritanrixTM-HepB/Hib intramuscularly in the left thigh at 6-10-14 weeks of...” NCT00814710 ↗ |
| Route | Intramuscular | “TritanrixTM-HepB/Hib intramuscularly in the left thigh” NCT00814710 ↗ |